<p><strong>大自然药业公司</strong> (NASDAQ:UPC) 的股票在过去一个月表现糟糕，损失了 31%，而在此之前的表现相对较好。最近的下跌使得股东在过去一年中面临灾难性的损失，损失幅度达到 95%。</p>
<p>在价格大幅下跌后，考虑到几乎一半的美国制药行业公司市销率（&#34;P/S&#34;）超过 4.1 倍，甚至市销率超过 20 倍的情况并不罕见，当前的大自然药业可能看起来是一个强有力的买入机会，其市销率为 0.1 倍。然而，我们需要更深入地研究，以确定这种大幅降低的市销率是否有合理的基础。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>查看我们对大自然药业的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629"/></p>
<p>NasdaqCM:UPC 市销率与行业比较 2025 年 11 月 25 日</p>
<h3>大自然药业的表现如何</h3>
<p>举个例子，过去一年中大自然药业的收入有所下降，这并不是一个理想的情况。许多人可能预期这种令人失望的收入表现将继续或加速，这抑制了市销率。看好大自然药业的人希望情况并非如此，以便他们能够以较低的估值买入该股票。</p>
<p>我们没有分析师的预测，但您可以通过查看我们对大自然药业的 <strong>免费</strong> 报告，了解最近的趋势如何为公司的未来铺路，包括收益、收入和现金流。</p>
<h2>大自然药业是否有收入增长的预测？</h2>
<p>有一个内在的假设，即公司应该远远低于行业表现，才能使像大自然药业这样的市销率被认为是合理的。</p>
<p>在回顾过去一年的财务数据时，我们感到沮丧，因为公司的收入下降了 28%。过去三年的表现也不理想，公司总收入缩水了 60%。因此，可以公平地说，最近的收入增长对公司来说是不可取的。</p>
<p>与公司相比，行业的其他部分预计在未来一年将增长 23%，这确实让公司的近期中期收入下降显得更加突出。</p>
<p>鉴于此，理解大自然药业的市销率低于大多数其他公司的原因是可以理解的。然而，随着收入的下滑，市销率是否已经触底并没有保证。即使只是维持这些价格也可能很困难，因为最近的收入趋势已经对股价造成了压力。</p>
<h2>我们可以从大自然药业的市销率中学到什么？</h2>
<p>大自然药业的市销率最近看起来和其股价一样疲软。虽然市销率不应该是决定是否购买股票的唯一因素，但它确实是收入预期的一个有效晴雨表。</p>
<p>正如我们所怀疑的，我们对大自然药业的调查显示，其中期收入的下降正在导致其低市销率，考虑到行业预计将增长。目前，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。除非近期的中期条件改善，否则它们将继续在这些水平上形成股价的障碍。</p>
<p>始终需要考虑投资风险的潜在威胁。我们已识别出 <strong>大自然药业的 4 个警示信号</strong>，理解这些信号应该是您投资过程的一部分。</p>
<p>重要的是要 <strong>确保您寻找的是一家优秀的公司，而不仅仅是您遇到的第一个想法。</strong> 如果持续盈利能力符合您对优秀公司的定义，请查看这份 <strong>免费</strong> 的有趣公司名单，这些公司最近的盈利增长强劲且市盈率较低。</p>

大自然药业

<p>宇宙药业公司 (NASDAQ:UPC) 的股价在一个月内下跌了 31%，过去一年累计损失达 95%。尽管市销率仅为 0.1 倍，但去年收入下降了 28%，三年内下降了 60%，与行业预期的 23% 增长形成鲜明对比。公司的财务困境导致其股价低迷，且没有立即改善收入的迹象</p>

<p><strong>Universe Pharmaceuticals INC</strong> (NASDAQ:UPC) shares have had a horrible month, losing 31% after a relatively good period beforehand. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 95% loss during that time.</p>
<div class="lb-trans"><p><strong>大自然药业公司</strong> (NASDAQ:UPC) 的股票在过去一个月表现糟糕，损失了 31%，而在此之前的表现相对较好。最近的下跌使得股东在过去一年中面临灾难性的损失，损失幅度达到 95%。</p>
</div><p>Following the heavy fall in price, Universe Pharmaceuticals may look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 0.1x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 4.1x and even P/S higher than 20x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.</p>
<div class="lb-trans"><p>在价格大幅下跌后，考虑到几乎一半的美国制药行业公司市销率（&#34;P/S&#34;）超过 4.1 倍，甚至市销率超过 20 倍的情况并不罕见，当前的大自然药业可能看起来是一个强有力的买入机会，其市销率为 0.1 倍。然而，我们需要更深入地研究，以确定这种大幅降低的市销率是否有合理的基础。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>See our latest analysis for Universe Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对大自然药业的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629" alt="" original-src="https://images.simplywall.st/asset/chart/684099523-ps-multiple-vs-industry-1-dark-2/1764065756629"/></p>
<p>NasdaqCM:UPC Price to Sales Ratio vs Industry November 25th 2025</p>
<div class="lb-trans"><p>NasdaqCM:UPC 市销率与行业比较 2025 年 11 月 25 日</p>
</div><h3>How Universe Pharmaceuticals Has Been Performing</h3>
<div class="lb-trans"><h3>大自然药业的表现如何</h3>
</div><p>As an illustration, revenue has deteriorated at Universe Pharmaceuticals over the last year, which is not ideal at all. It might be that many expect the disappointing revenue performance to continue or accelerate, which has repressed the P/S. Those who are bullish on Universe Pharmaceuticals will be hoping that this isn't the case so that they can pick up the stock at a lower valuation.</p>
<div class="lb-trans"><p>举个例子，过去一年中大自然药业的收入有所下降，这并不是一个理想的情况。许多人可能预期这种令人失望的收入表现将继续或加速，这抑制了市销率。看好大自然药业的人希望情况并非如此，以便他们能够以较低的估值买入该股票。</p>
</div><p>We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our <strong>free</strong> report on Universe Pharmaceuticals' earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>我们没有分析师的预测，但您可以通过查看我们对大自然药业的 <strong>免费</strong> 报告，了解最近的趋势如何为公司的未来铺路，包括收益、收入和现金流。</p>
</div><h2>Is There Any Revenue Growth Forecasted For Universe Pharmaceuticals?</h2>
<div class="lb-trans"><h2>大自然药业是否有收入增长的预测？</h2>
</div><p>There's an inherent assumption that a company should far underperform the industry for P/S ratios like Universe Pharmaceuticals' to be considered reasonable.</p>
<div class="lb-trans"><p>有一个内在的假设，即公司应该远远低于行业表现，才能使像大自然药业这样的市销率被认为是合理的。</p>
</div><p>In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 28%. The last three years don't look nice either as the company has shrunk revenue by 60% in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>在回顾过去一年的财务数据时，我们感到沮丧，因为公司的收入下降了 28%。过去三年的表现也不理想，公司总收入缩水了 60%。因此，可以公平地说，最近的收入增长对公司来说是不可取的。</p>
</div><p>In contrast to the company, the rest of the industry is expected to grow by 23% over the next year, which really puts the company's recent medium-term revenue decline into perspective.</p>
<div class="lb-trans"><p>与公司相比，行业的其他部分预计在未来一年将增长 23%，这确实让公司的近期中期收入下降显得更加突出。</p>
</div><p>In light of this, it's understandable that Universe Pharmaceuticals' P/S would sit below the majority of other companies. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. Even just maintaining these prices could be difficult to achieve as recent revenue trends are already weighing down the shares.</p>
<div class="lb-trans"><p>鉴于此，理解大自然药业的市销率低于大多数其他公司的原因是可以理解的。然而，随着收入的下滑，市销率是否已经触底并没有保证。即使只是维持这些价格也可能很困难，因为最近的收入趋势已经对股价造成了压力。</p>
</div><h2>What We Can Learn From Universe Pharmaceuticals' P/S?</h2>
<div class="lb-trans"><h2>我们可以从大自然药业的市销率中学到什么？</h2>
</div><p>Universe Pharmaceuticals' P/S looks about as weak as its stock price lately. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>大自然药业的市销率最近看起来和其股价一样疲软。虽然市销率不应该是决定是否购买股票的唯一因素，但它确实是收入预期的一个有效晴雨表。</p>
</div><p>As we suspected, our examination of Universe Pharmaceuticals revealed its shrinking revenue over the medium-term is contributing to its low P/S, given the industry is set to grow. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises either. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>正如我们所怀疑的，我们对大自然药业的调查显示，其中期收入的下降正在导致其低市销率，考虑到行业预计将增长。目前，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。除非近期的中期条件改善，否则它们将继续在这些水平上形成股价的障碍。</p>
</div><p>It's always necessary to consider the ever-present spectre of investment risk. We've identified <strong>4 warning signs with Universe Pharmaceuticals</strong>, and understanding these should be part of your investment process.</p>
<div class="lb-trans"><p>始终需要考虑投资风险的潜在威胁。我们已识别出 <strong>大自然药业的 4 个警示信号</strong>，理解这些信号应该是您投资过程的一部分。</p>
</div><p>It's important to <strong>make sure you look for a great company, not just the first idea you come across.</strong> So if growing profitability aligns with your idea of a great company, take a peek at this <strong>free</strong> list of interesting companies with strong recent earnings growth (and a low P/E).</p>
<div class="lb-trans"><p>重要的是要 <strong>确保您寻找的是一家优秀的公司，而不仅仅是您遇到的第一个想法。</strong> 如果持续盈利能力符合您对优秀公司的定义，请查看这份 <strong>免费</strong> 的有趣公司名单，这些公司最近的盈利增长强劲且市盈率较低。</p>
</div>

投资者看不到大自然药业公司（NASDAQ:UPC）隧道尽头的曙光，导致股价下跌 31%